Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT06174220

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06174220
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06174220. Randomized; quadruple masking; primary purpose treatment. Start 2025-03-21 (actual); primary completion 2027-02-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
Acronym
TaRGET
Condition
Arrhythmogenic Cardiomyopathy
Condition
Arrhythmogenic Right Ventricular Cardiomyopathy
Intervention (Drug)
Tideglusib
Intervention (Drug)
Placebo
Lead sponsor
Hamilton Health Sciences Corporation (class: other)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)
Collaborator
Canadian SADS (class: not stated)
Collaborator
AMO Pharma Limited (class: industry)
Collaborator
Hearts in Rhythm Organization (HiRO) (class: not stated)
Collaborator
Population Health Research Institute (class: other)

Record details

Record id
cardio:ct-nct06174220
Content hash
5b2880083c4ce9832e22ccd7a521279a26cb00be9b376f6395e730c8c92955fd